Nano-scavengers for blood biomarker discovery in ovarian carcinoma
Hadjidemetriou, Marilena (The University of Manchester. Nanomedicine Lab)
Papafilippou, Lana (The University of Manchester. Nanomedicine Lab)
Unwin, Richard D. (The University of Manchester. Division of Cardiovascular Sciences)
Rogan, Jane (Manchester Cancer Research Centre Biobank)
Clamp, Andrew (The University of Manchester. Manchester Cancer Research Centre)
Kostarelos, Kostas (Institut Català de Nanociència i Nanotecnologia)

Data:	2020
Resum:	The development and implementation of biomarker-based screening tools for ovarian cancer require novel analytical platforms to enable the discovery of biomarker panels that will overcome the limitations associated with the clinically used CA-125. The systematic discovery of protein biomarkers directly from human plasma using proteomics remains extremely challenging, due to the wide concentration range of plasma proteins. Here, we describe the use of lipid-based nanoparticles (NPs) as an 'omics' enrichment tool to amplify cancer signals in the blood and to uncover disease specific signatures. We aimed to exploit the spontaneous interaction of clinically-used liposomes (Caelyx®) with plasma proteins, also known as' protein corona' formation, in order to facilitate the discovery of previously unreported differentially abundant molecules. Caelyx® liposomes were incubated with plasma samples obtained from advanced ovarian carcinoma patients and healthy donors and corona-coated liposomes were subsequently recovered. Comprehensive comparison between 'healthy' and 'diseased' corona samples by label-free proteomics resulted in the identification of multiple differentially abundant proteins. Moreover, immunoassay-based validation of selected proteins demonstrated the potential of nanoparticle-platform proposed to discover novel molecules with great diagnostic potential. This study proposes a nanoparticle-enabled workflow for plasma proteomic analysis in healthy and diseased states and paves the way for further work needed to discover and validate panels of novel biomarkers for disease diagnosis and monitoring.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió acceptada per publicar
Matèria:	Protein corona ; Biomarkers ; Ovarian cancer ; Liposomes ; Nanomedicine
Publicat a:	Nano Today, Vol. 34 (Oct. 2020) , art. 100901, ISSN 1878-044X

DOI: 10.1016/j.nantod.2020.100901

Postprint 24 p, 881.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats